Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paridaens, R.
Right arrow Articles by Azli, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paridaens, R.
Right arrow Articles by Azli, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:433-440, 2003
© 2003 European Society for Medical Oncology

Original Paper

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer

R. Paridaens1,+, F. Van Aelst2, V. Georgoulias3, H. Samonnig4, V. Cocquyt5, C. Zielinski6, H. Hausmaninger7, P. Willemse8, Y. Boudraa9, J. Wildiers1, C. Ramazeilles9 and N. Azli9

1 University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven; 2 H. Hartziekenhuis Hospital, Roeselare, Belgium; 3 University Hospital of Heraclion, Crete, Greece; 4 University of Graz, Graz, Austria; 5 University Hospital of Gent, Gent, Belgium; 6 University of Vienna, Vienna; 7 General Hospital Salzburg, Salzburg, Austria; 8 Academic Hospital Groningen, Groningen, The Netherlands; 9 Aventis Pharma Inc., Antony, France

Received 15 May 2002; revised 7 October 2002; accepted 30 October 2002

Background:

This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC).

Patients and methods:

Women with MBC requiring first-line chemotherapy for progressive disease (n = 106) were randomized and received 3-weekly monotherapy with docetaxel (T, 100 mg/m2, 1-h i.v. infusion) and doxorubicin (A, 75 mg/m2, 20–30-min i.v. infusion) either on a cycle-by-cycle alternating basis (ATATATAT, n = 51) or sequentially each for four cycles (TTTTAAAA, n = 55).

Results:

For both regimens, the median number of cycles administered was the maximum of eight. The alternating and sequential groups achieved similar objective tumor response rates (60% and 67%, respectively) and similar median duration of response (47 and 44 weeks, respectively). With a median follow-up of 31 months, median survival times were estimated at 20 and 26 months in the alternating and sequential groups, respectively. No unexpected toxicities were reported. Compared with alternating therapy, patients receiving sequential therapy were more likely to complete the planned eight chemotherapy cycles (69% versus 63%), and had a lower incidence of febrile neutropenia (2% versus 14%).

Conclusions:

Alternating and sequential docetaxel–doxorubicin regimens are viable alternatives to simultaneous combination therapy in MBC, with sequential therapy achieving slightly higher response rates and improved tolerability compared with alternating therapy.

Key words: alternating, breast cancer, chemotherapy, docetaxel, doxorubicin, sequential


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
H. Joensuu, L. Sailas, T. Alanko, K. Sunela, R. Huuhtanen, M. Utriainen, R. Kokko, P. Bono, T. Wigren, S. Pyrhonen, et al.
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Ann. Onc., October 9, 2009; (2009) mdp397v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al.
Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Chan, N. Davidson, E. Juozaityte, F. Erdkamp, A. Pluzanska, N. Azarnia, and L. W. Lee
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer
Ann. Onc., October 1, 2004; 15(10): 1527 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al.
Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study
J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al.
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
Ann. Onc., March 1, 2004; 15(3): 433 - 439.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.